Long-Term Benefit With Abemaciclib in High-Risk Early Breast Cancer
The benefit was maintained beyond the 2-year treatment period.
Breast Cancer
BREAST CANCER ADVISOR
FEATURED CONTENT
-
-
PTSD in Cancer Patients: What Providers Need to Know
Experts outline risk factors for PTSD and explain how PTSD can affect cancer outcomes. -
How to Prevent a Cyberattack from Derailing Cancer Care
Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care. -
Updated Screening Guidelines for 5 Cancer Types
An update on the available cancer screening guidelines, benefits/limitations, and risks for cervical, breast, prostate, colon, and lung cancers. -
Changes in Clinical Trial Conduct Prompted by the COVID-19 Pandemic Should Persist
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
VIDEO SERIES
The Phase 3 PlanB Trial
Continue to Work?
2016 SABCS: Clinical Insights Telli
2016 SABCS: Clinical Insights Oregan
HER2-positive Metastatic and TNBC
Frontline Treatments
Treatment-related Neuropathy
ER-positive, HER2-negative
Emerging Medicines
Triple-negative Breast Cancer
Insights from the Lab and Clinic
Trastuzumab Resistance
Biologic Role of HER2
Strategies in Management
BREAST CANCER NEWS
Elacestrant Improved PFS in Metastatic Breast Cancer Progressing on CDK4/6 Therapy
First-Line Ribociclib/Letrozole Effective in Breast Cancer Across Subgroups
Increasing Marker Clip Placement During Ultrasound-Guided Breast Biopsy
Recurrence Risk Reduced With AI vs Tamoxifen in Premenopausal ER+ Breast Cancer
Genomic-Based Targeted Therapy Improved PFS for Certain Metastatic Breast Cancers
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Breast Cancer
Loading... 
Loading...